TOMEGAVAX
TomegaVax Inc. is an immunotherapy company that applies a game-changing vaccine technology platform to areas of unmet medical need. The company is focused on the preclinical and clinical development of vaccines and immunotherapies for chronic and recurring viral infections including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV).
TOMEGAVAX
Industry:
Biotechnology Health Care
Founded:
2011-01-01
Address:
Beaverton, Oregon, United States
Country:
United States
Website Url:
http://www.tomegavax.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
SPF Apache Microsoft Azure DNS GoDaddy DNS Sectigo SSL Sectigo Domain SSL Proofpoint
Similar Organizations
Antoxis
Antoxis is developing treatments for various neurological conditions.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Official Site Inspections
http://www.tomegavax.com
- Host name: ip-143-95-225-66.iplocal
- IP address: 143.95.225.66
- Location: Los Angeles United States
- Latitude: 34.0549
- Longitude: -118.2578
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90014
More informations about "TomegaVax"
TomegaVax - Crunchbase Company Profile & Funding
TomegaVax Inc. is an immunotherapy company that applies a game-changing vaccine technology platform to areas of unmet medical need. The company is focused on the preclinical and …See details»
TomegaVax Company Profile 2024: Valuation, Funding & Investors …
TomegaVax General Information Description. Developer of an immunotherapy vaccine technology platform designed for treating chronic and recurring viral infections. The company's platform …See details»
Tomegavax, Inc. Company Profile | Portland, OR | Competitors ...
Find company research, competitor information, contact details & financial data for Tomegavax, Inc. of Portland, OR. Get the latest business insights from Dun & Bradstreet.See details»
OHSU-developed vaccine shows promise for cancer …
May 28, 2024 Früh and his colleagues Louis Picker, M.D., professor in VGTI, and Scott Hansen, Ph.D., associate professor in VGTI, have been working on developing this vaccine platform since the early 2000s.In 2016, their OHSU …See details»
Vaccine technology developed by OHSU scientists acquired by …
Jan 25, 2017 The acquisition, which includes a merger with the OHSU startup TomegaVax Inc., is a critical step in translating a basic science concept pioneered at OHSU into a portfolio of …See details»
20 Things You Didn’t Know About Vir Technology
Dec 17, 2021 6. It also acquired TomegaVax. Vir announced its acquisition of the TomegaVax organization on January 6, 2017. TomegaVax is a biotechnology company that conducts research for teh development of cures for a variety of …See details»
New vaccine approaches present new possibilities, but …
Jun 1, 2021 Vir Biotechnology licensed the platform through a merger with the OHSU spinout, TomegaVax and now has VIR-1111 in phase 1 trials. Nabel also noted that nanoparticle technologies are promising ...See details»
Research programme: CMV-based HPV vaccines - Vir Biotechnology
Vir Biotechnology (previously TomegaVax) is using its proprietary recombinant cytomegalovirus (CMV) vaccine technology platform to develop a vaccine for the Research programme: CMV …See details»
From the Portland Business Journal - OHSU
And acquired the OHSU spinoff TomegaVax in late 2016. The trial is a milestone for the research begun by Dr. Louis Picker about two decades ago. The platform is designed to elicit abundant …See details»
Sanofi to work with Immune Design on herpes vaccine - PMLiVE
Oct 17, 2014 Sanofi has joined forces with US biotech Immune Design to accelerate development of the first therapeutic vaccine against genital herpes. Despite decades of …See details»
Peptide Processing Is Critical for T-Cell Memory …
Dec 15, 2016 Competing interests: The authors declare the following competing financial interest: Oregon Health and Science University (OHSU) and KF have a significant financial interest in TomegaVax Inc., a company that may have a …See details»
TomegaVax - Products, Competitors, Financials, Employees, …
The property rights to the platform have been owned by TomegaVax, which OHSU created in 2011 to eventually get Picker’s technology commercialized. Scientists at academic research …See details»
Research programme: CMV-based malaria vaccines - Vir …
Vir Biotechnology (previously TomegaVax) is using its proprietary recombinant cytomegalovirus (CMV) vaccine technology platform to develop a vaccine for theSee details»
Why a new efficacious TB vaccine is likely | LSHTM
Add to Calendar 2016-06-30 18:15:00 2016-06-30 01:00:00 Why a new efficacious TB vaccine is likely Thomas G. Evans, MD – Chief Medical Officer Tom brings a wealth of expertise to the …See details»
Research programme: CMV-based herpes simplex virus vaccines
Vir Biotechnology (previously TomegaVax) was using its proprietary recombinant cytomegalovirus (CMV) vaccine technology platform to develop a vaccine for the Research programme: CMV …See details»
Development of Direct-acting Antiviral and Host-targeting Agents …
TomegaVax HBV: therapeutic vaccine: preclinical: TomegaVax: sponsor’s web site: MVA-VLP-HBV: therapeutic vaccine: preclinical: GeoVax and CaroGen: sponsor’s web site ... et al. …See details»
Research programme: hepatitis B virus vaccines - Vir …
Vir Biotechnology (previously TomegaVax) is using its proprietary recombinant cytomegalovirus (CMV) vaccine technology platform to develop a vaccine for theSee details»
TomegaVax - Company Profile - Tracxn
TomegaVax - Developing cytomegalovirus-vector based vaccines for viral infections. from 2 investors. TomegaVax has 371 competitors.See details»
VIR 2020 - AdisInsight
VIR 2020 is a human cytomegalovirus based, tuberculosis T cell vaccine being developed by Vir Biotechnology (previously TomegaVax) by using its proprietary VIR 2020 Next ... If your …See details»
VIR 1111 - AdisInsight - Springer
VIR 1111 is a subcutaneously administered, HIV T-cell vaccine based on human cytomegalovirus (HCMV), being developed by Vir Biotechnology (previously TomegaVax) VIR 1111 - …See details»